ELRIG UK’s Post

I am really impressed by the systematic approach the authors took in investigating the data we all have been extracting over the years. By integrating CPTAC proteogenomics data from 1,043 patients across 10 cancer types with additional public datasets, they identified potential therapeutic targets. This comprehensive analysis offers valuable insights for drug repurposing and therapy development. Truly great work! Explore the findings here: https://lnkd.in/dbgX2w_Q https://lnkd.in/dbgX2w_Q #CancerResearch #Proteomics #DrugDiscovery #Bioinformatics

🎉 Proud moment for COVALAB! 🎉 We are thrilled to announce that our PhD candidate, Anna BÉROT , has published her first research article🏆Her work explores the development of 𝗶𝗺𝗺𝘂𝗻𝗼𝗹𝗶𝗽𝗼𝘀𝗼𝗺𝗲𝘀 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗛𝗘𝗥𝟮-𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗲𝗹𝗹𝘀, exploiting our proprietary 𝗖𝗢𝗩𝗜𝗦𝗢𝗟𝗜𝗡𝗞 technology. 🔬 This innovative study showcases the potential of nanocarriers in drug delivery, specifically by attaching antibodies to liposomes, creating highly targeted treatments. Unlike traditional methods, which can compromise the antibody's stability and efficacy, our 𝗖𝗢𝗩𝗜𝗦𝗢𝗟𝗜𝗡𝗞 technology approach ensure precise and stable conjugation, leading to optimized results. This achievement reflects not only Anna’s hard work and specialization but also the strength of our R&D team. Our collaborative environment drives innovation, and this achievement shows what we can accomplish together. 🌟 Join us in congratulating Anna for her hard work! #liposome #HER2 #drugdelivery #biotechnology

Check out the "Antibodies to Watch in 2024" 👀 Antibody therapeutics are consistently surpassing small-molecule drugs in their approval success rates. Here are some noteworthy highlights that caught our attention: 💡 For both cancer and non-cancer indications, ~60% of the molecules target novel antigens. 💡 Among early-stage cancer antibodies, around 33% exhibit multispecific properties. Of the monospecifics, about 33% are Antibody-Drug Conjugates (ADCs). 💡 Of the early-stage antibodies for non-cancer indications, most are monospecific, with only 12% that are multispecific. #antibodytherapeutics #antibodydevelopment

🚀 🎉 Happy New Year to all my LinkedIn contacts! Excited to kick off 2024 with my first post and exciting news from the Antibody World! 🧬 📢 Just read the "Antibodies to Watch in 2024" paper in the journal mAbs. This annual publication offers a fascinating overview of antibody-based therapeutic products currently under development. 🔬 This year's edition highlights 16 newly approved antibody therapeutics in 2023, and discusses 26 candidates undergoing regulatory review. It's a mix of treatments for cancer and non-cancer indications, showcasing the vibrant innovation in this field. 🧪 The success rates and the development of these therapeutics reflect a robust and increasingly successful industry trend. Particularly, the rise in bispecific antibodies and antibody-drug conjugates points towards a promising future in medicine. 🔗 https://lnkd.in/eeRE-RZM #AntibodyTherapeutics #BiomedicalResearch #InnovationInHealthcare #mAbsJournal Silvia Crescioli Hélène Kaplon Alicia Chenoweth Lin Wang Jyothsna Visweswaraiah Janice Reichert

🔬 This #biopharma animation developed by our team showcases humabodies as potential cancer therapeutics and explains their features. Our client is developing humabodies as a new type of therapeutic agent. These humabodies offer advantages over traditional biospecific antibodies as they are smaller, more robust, and easier to engineer. Their small size improves drugability and bioavailability, making them suitable for various applications. Our client's focus on humabodies represents an innovative approach to cancer therapeutics, offering unique benefits in engaging therapeutic targets and expanding treatment possibilities. Want to learn more about our work? Visit our site via the link in the comments section👇 #medicalanimation #pharma #biotechnology #molecularbiology #cancerresearch #cancertreatment #moaanimation

As we approach the 15th Annual @World ADC meeting in San Diego, we are excited to explore potential partnerships and collaborations in the cutting-edge field of Antibody Drug Conjugates (ADCs) for oncology. ADCs are transforming cancer treatment by precisely targeting cancer cells, administering potent therapies directly where they are needed, while protecting healthy tissue in the process. We are particularly looking forward to Scientific Officer Lynn Kamen’s presentation titled, "Bioanalytical Strategies for Antibody Drug Conjugate Development," scheduled for November 5th from 6:30-7:30 PM. In her talk, Dr. Kamen will delve into vital bioanalytical strategies for assessing ADC pharmacokinetics and immunogenicity, emphasizing the significance of both molecular components for ensuring efficacy and safety. Join us in connecting with researchers and industry leaders as we work towards advancing oncology treatments. We can't wait to see you at booth 518 in San Diego! https://bit.ly/4dTJZVa #WorldADC #ADC #PharmaInnovation #Biotech #DrugDevelopment #BioAgilytix #AntibodyDrugConjugates #InnovationInBiotech

We're counting down to IO360! Don't miss the panel presentation, State of the IO Market, Investments, and Deals: Investment Trends in IO, featuring Lumanity's Jeff Bockman. For more information, visit and use code "LUM20" for a 20% discount on your registration, and be sure to schedule time to connect with us on-site at contact@lumanity.com. #IO360nyc #Immunology #Oncology #Pharma #Biotech #ImmunoOncology #IO360

Excited to share my #RSCPoster for the RSC Poster Conference 2024 titled, "Appropriate formulation of imidazopyridine-based thiazole derivative as a potent treatment for triple-negative breast cancer". The snippet from our work is as follows, "The prognosis is detrimental for fatal breast cancers, such as triple-negative breast cancer (TNBC). The rate-limiting enzyme in glycolysis, pyruvate kinase M2 (PKM2), is unusually elevated in TNBC. PKM2 overexpression speeds up the development of carcinogenic processes by increasing the intake of glucose, increasing the synthesis of lactate, and inhibiting autophagy. A high death rate necessitates the immediate use of innovative chemotherapy regimens. Here, we report the rational development of thiazole derivative 7d, which is based on imidazopyridine, as an anti-cancer drug that inhibits PKM2. Enzyme tests led to the discovery of PKM2 inhibitors in the nanomolar range with advantageous drug-like characteristics. Preclinical validation of 7d was achieved by experiments conducted on 2D/3D cell cultures, lactate release tests, surface plasmon resonance (SPR), and qRT-PCR. 7d was more effective in regressing tumors in vivo than lapatinib. In order to treat TNBC, this study presents a lead-based strategy that is distinguished by its robust effectiveness and straightforward chemistry for the synthesis of an incredibly strong inhibitor that targets PKM2."  Chemical Biology #RSCChemBio#RSCChemBio #RSCPoster #RSCChemBio ErrantScience

The Phase 1a clinical trial for Anixa’s #breastcancer vaccine in development focuses on women who have had #TNBC and have undergone standard of care, but are at risk of recurrence. As of March 2024, 25 patients have been dosed. Positive clinical results: - No safety concerns - Immune responses observed at all dose levels - All patients had some immune response - Intensity of responses varied with patients Keep up with our latest developments: https://bit.ly/3xpCWnU #Oncology #Biotechnology #Biotech #Biosciences #ClinicalTrials #CancerResearch

An exciting new #cryoEM paper out now in Nature Communications features research from collaborators across Thermo Fisher Scientific, The Institute of Cancer Research, Imperial College London & Carrick Therapeutics: "We have now demonstrated that current cryo-EM technology is suitable for routine 2 Å structure determination of small protein complexes from less than one day of data collection on a high-end system, opening the door to high-throughput, high-resolution cryo-EM even for nominally difficult targets." Read the full study to learn how their results establish a methodological framework for the use of high-resolution cryo-EM in structure-based #DrugDesign ⬇️ https://ter.li/v95xt8